Dozy do
14 December 2016
Email
Share
The French firm is mooted as a buyer for the Swiss biotech group after J&J walked away. The financial logic looks equally strained, and overpaying would smack of desperation about Sanofi’s own business. With drug prices under pressure, pharma M&A will not get any more rational.
This content is for Subscribers only
To access full Breakingviews.com content you must be a subscriber. Please use the following link to request a trial.